Advertisement

Topics

Stereotaxis achieves record recurring revenue for 2018, continues to invest in R&D

05:05 EDT 26 Mar 2019 | Proactive Investors

Stereotaxis Inc (OTCQX:STSX) CEO David Leo Fischel tells Proactive Investors that the robotic technologies company that designs robotics instruments to treat heart arrhythmias and perform endovascular procedures, has posted record recurring revenue for 2018.

Fischel says despite investing more than $8 million in R&D last year, the company has achieved record recurring revenue of $27.8 million.

Original Article: Stereotaxis achieves record recurring revenue for 2018, continues to invest in R&D

NEXT ARTICLE

More From BioPortfolio on "Stereotaxis achieves record recurring revenue for 2018, continues to invest in R&D"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...